PMID: 15378132Sep 21, 2004Paper

Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent

Journal of Cardiovascular Pharmacology and Therapeutics
Charles AntzelevitchGuillermo Perez

Abstract

Ranolazine is a novel antianginal agent capable of producing anti-ischemic effects at plasma concentrations of 2 to 6 microM without a significant reduction of heart rate or blood pressure. This review summarizes the electrophysiologic properties of ranolazine. Ranolazine significantly blocks I(Kr) (IC(50) = 12 microM), late I(Na), late I(Ca), peak I(Ca), I(Na-Ca) (IC(50) = 5.9, 50, 296, and 91 microM, respectively) and I(Ks) (17% at 30 microM), but causes little or no inhibition of I(to) or I(K1). In left ventricular tissue and wedge preparations, ranolazine produces a concentration-dependent prolongation of action potential duration (APD) in epicardium, but abbreviation of APD of M cells, leading to either no change or a reduction in transmural dispersion of repolarization (TDR). The result is a modest prolongation of the QT interval. Prolongation of APD and QT by ranolazine is fundamentally different from that of other drugs that block I(Kr) and induce torsade de pointes in that APD prolongation is rate-independent (ie, does not display reverse rate-dependent prolongation of APD) and is not associated with early after depolarizations, triggered activity, increased spatial dispersion of repolarization, or polymorphic ventricu...Continue Reading

References

Jul 1, 1992·European Heart Journal·M ZimmermannA Bloch
Jan 1, 1990·Pacing and Clinical Electrophysiology : PACE·R M CampbellD M Roden
Dec 15, 1990·JAMA : the Journal of the American Medical Association·B P MonahanL R Cantilena
Nov 1, 1986·Pacing and Clinical Electrophysiology : PACE·A E AldarizR J Esper
May 1, 1986·American Heart Journal·J ManouvrierG Ducloux
Mar 15, 1985·The American Journal of Cardiology·E N Prystowsky
Feb 1, 1984·British Heart Journal·J K McKibbinI W Obel
Nov 1, 1983·Journal of the American College of Cardiology·G N KayA L Waldo
Nov 1, 1994·The American Journal of Cardiology·G CuiB N Singh
Feb 1, 1994·Journal of the American College of Cardiology·G MalfattoP J Schwartz
Feb 1, 1994·Chest·B GitlerS D Buffa
Nov 1, 1995·Journal of Cardiovascular Pharmacology·B Le GrandG W John
Jul 25, 1996·The New England Journal of Medicine·D K Wysowski, J Bacsanyi
Jul 1, 1996·Journal of the American College of Cardiology·K A EllenbogenJ T Vanderlugt
Nov 15, 1996·Circulation·M H LehmannD J MacNeil

❮ Previous
Next ❯

Citations

Oct 31, 2012·Cardiovascular Drugs and Therapy·Alexander Burashnikov, Charles Antzelevitch
Dec 19, 2012·Cardiovascular Drugs and Therapy·Neil J Wimmer, Peter H Stone
Feb 25, 2010·Nature Reviews. Cardiology·Alexander Burashnikov, Charles Antzelevitch
Sep 7, 2007·The New England Journal of Medicine·Bramah N SinghUNKNOWN EURIDIS and ADONIS Investigators
Nov 21, 2007·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Charles Antzelevitch
Oct 27, 2009·American Journal of Physiology. Heart and Circulatory Physiology·William H BarryThomas P Kennedy
Nov 16, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Hai HuangMohamed Chahine
Dec 3, 2009·Circulation. Arrhythmia and Electrophysiology·Serge SicouriCharles Antzelevitch
Dec 25, 2012·Future Cardiology·Jordi HeijmanDobromir Dobrev
Aug 15, 2014·Nature Communications·Shenghui LiangYuchun Gu
Sep 8, 2006·Current Cardiology Reports·Bramah N Singh
Sep 27, 2005·Expert Review of Cardiovascular Therapy·William C Stanley
May 27, 2009·Expert Opinion on Emerging Drugs·Alexander Burashnikov, Charles Antzelevitch
Aug 25, 2012·Expert Opinion on Investigational Drugs·Stylianos Tzeis, George Andrikopoulos
Apr 2, 2015·International Journal of Cardiology·Tanush GuptaSei Iwai
Jul 25, 2012·Neuroscience Letters·Hiroyuki Nodera, Seward B Rutkove
Apr 18, 2009·Journal of Molecular and Cellular Cardiology·N LindeggerR S Kass
Apr 18, 2009·Toxicology and Applied Pharmacology·Shigeyuki YamadaWilliam H Barry
Jul 22, 2015·Nature Reviews. Cardiology·Gerrit Frommeyer, Lars Eckardt
Nov 29, 2007·Pharmacotherapy·Paul P Dobesh, Toby C Trujillo
Oct 5, 2010·Pacing and Clinical Electrophysiology : PACE·Dipak P ShahMartin C Burke
Oct 16, 2015·Clinical Cardiology·Marwan SaadC Richard Conti
Jul 5, 2005·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Rashmi R Shah, Luc M Hondeghem
Mar 28, 2012·European Journal of Pharmacology·Chun-Yu DengShu-Guang Lin
Jan 15, 2011·Journal of the American College of Cardiology·Norishige MoritaHrayr S Karagueuzian
Jun 1, 2014·Journal of Molecular and Cellular Cardiology·Chunyun DuJules C Hancox
Feb 27, 2016·Expert Opinion on Therapeutic Targets·Jules C HancoxDierk Thomas
Mar 23, 2011·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Charles AntzelevitchLuiz Belardinelli
Oct 9, 2016·Drug Discovery Today·Barbara Wiśniowska, Sebastian Polak
Jul 19, 2005·Toxicology and Applied Pharmacology·T G Hammond, C E Pollard
Jan 15, 2014·Expert Review of Cardiovascular Therapy·Raj Parikh, Philip J Kadowitz
Sep 21, 2004·Journal of Cardiovascular Pharmacology and Therapeutics·Bernard R Chaitman
Oct 27, 2017·Journal of Cardiovascular Pharmacology·Helena CarstensenThomas Jespersen
May 24, 2014·Cardiology·Sahil KheraWilbert S Aronow
Oct 14, 2016·Circulation. Arrhythmia and Electrophysiology·Ehud ChorinSami Viskin
Mar 21, 2017·Circulation. Arrhythmia and Electrophysiology·Mohammed Ali AzamKumaraswamy Nanthakumar
May 12, 2006·Journal of Cardiovascular Electrophysiology·Charles Antzelevitch, Luiz Belardinelli
Jan 21, 2019·Journal of Cardiovascular Electrophysiology·Helena CarstensenRikke Buhl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.